Abstract
Depression remains difficult to manage, despite the many registered treatments available. For many depressed individuals, particularly those who have not responded to and/or had adverse effects from standard therapies, herbal and natural medications represent a potentially valuable alternative. This chapter will review several natural remedies used in the treatment of depression. Specific remedies covered include St. John’s wort (SJW), S-adenosyl-L-methionine (SAMe), omega-3 fatty acids, rhodiola, and others. We will begin by providing some historical and social context about these remedies. Then we will review efficacy and safety data, as well as biological mechanisms of action of these therapies. Finally, we will discuss the limitations of the current state of knowledge and provide suggestions for a productive research agenda focused on natural remedies. While many questions about these treatments remain unanswered and much work needs to be done before we determine their place in the psychiatric armamentarium, we believe that this chapter will give psychiatrists a good perspective on the pros and cons of herbal and natural antidepressants as part of the pharmacological armamentarium and sensible guidelines on how and when they should be used.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Almeida OP, Ford AH, Flicker L (2015) Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr 27(5):727–737. https://doi.org/10.1017/S1041610215000046
Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y et al (2004) S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 24(6):661–664
Alpert JE, Papakostas GI, Mischoulon D (2008) One-carbon metabolism and the treatment of depression: roles of S-adenosyl methionine (SAMe) and folate. In: Mischoulon D, Rosenbaum J (eds) Natural medications for psychiatric disorders: considering the alternatives, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 68–83
Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JNV, Sorbero ME, Hempel S (2016) A systematic review of St. John’s wort for major depressive disorder. Syst Rev 5(1):148. https://doi.org/10.1186/s13643-016-0325-2
Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R (2016) ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open 6(3):e010172. https://doi.org/10.1136/bmjopen-2015-010172
Asher GN, Gartlehner G, Gaynes BN, Amick HR, Forneris C, Morgan LC et al (2017) Comparative benefits and harms of complementary and alternative medicine therapies for initial treatment of major depressive disorder: systematic review and meta-analysis. J Altern Complement Med (New York, NY). https://doi.org/10.1089/acm.2016.0261
Baede-van Dijk PA, van Galen E, Lekkerkerker JF (2000) Drug interactions of Hypericum perforatum (St. John’s wort) are potentially hazardous. Ned Tijdschr Geneeskd 144(17):811–812
Baraban JM, Worley PF, Snyder SH (1989) Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry 146(10):1251–1260. https://doi.org/10.1176/ajp.146.10.1251
Begtrup KM, Krag AE, Hvas A-M (2017) No impact of fish oil supplements on bleeding risk: a systematic review. Dan Med J 64(5)
Belmaker RH, Levine J (2008) Inositol in the treatment of psychiatric disorders. In: Mischoulon D, Rosenbaum JF (eds) Natural medications for psychiatry: considering the alternatives, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 105–115
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I et al (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biol Psychiatry 64(6):468–475. https://doi.org/10.1016/j.biopsych.2008.04.022
Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS et al (2011) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135(1–3):389–394. https://doi.org/10.1016/j.jad.2011.06.005
Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K et al (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 75(6):628–636. https://doi.org/10.4088/JCP.13m08454
Bersani G, Meco G, Denaro A, Liberati D, Colletti C, Nicolai R et al (2013) L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 23(10):1219–1225. https://doi.org/10.1016/j.euroneuro.2012.11.013
Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 17(12):1272–1282. https://doi.org/10.1038/mp.2011.100
Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope HG et al (2013) A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol 33(5):627–635. https://doi.org/10.1097/JCP.0b013e31829a83f5
Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I (1997) Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30(Suppl 2):94–101. https://doi.org/10.1055/s-2007-979527
Cassano P, Fava M (2004) Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 16(1):15–25
Chen F, Wen Q, Jiang J, Li H-L, Tan Y-F, Li Y-H, Zeng N-K (2016) Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol 179:253–264. https://doi.org/10.1016/j.jep.2015.12.031
Clauson KA, Santamarina ML, Rutledge JC (2008) Clinically relevant safety issues associated with St. John’s wort product labels. BMC Complement Altern Med 8:42. https://doi.org/10.1186/1472-6882-8-42
Cohen IJ (2017) Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol 79(6):1057–1065. https://doi.org/10.1007/s00280-017-3304-y
Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD et al (2010) Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 19(6):1632–1642. https://doi.org/10.1158/1055-9965.EPI-10-0180
Cropley M, Banks AP, Boyle J (2015) The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms. Phytother Res 29(12):1934–1939. https://doi.org/10.1002/ptr.5486
Data-Franco J, Singh A, Popovic D, Ashton M, Berk M, Vieta E et al (2017) Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology. Prog Neuro-Psychopharmacol Biol Psychiatry 72:73–86. https://doi.org/10.1016/j.pnpbp.2016.09.004
Davis SA, Feldman SR, Taylor SL (2014) Use of St. John’s wort in potentially dangerous combinations. J Altern Complement Med (New York, NY) 20(7):578–579. https://doi.org/10.1089/acm.2013.0216
de Sousa CNS, Meneses LN, Vasconcelos GS, Silva MCC, da Silva JC, Macêdo D et al (2015) Reversal of corticosterone-induced BDNF alterations by the natural antioxidant alpha-lipoic acid alone and combined with desvenlafaxine: emphasis on the neurotrophic hypothesis of depression. Psychiatry Res 230(2):211–219. https://doi.org/10.1016/j.psychres.2015.08.042
Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI (2012) SAMe and sexual functioning. Eur Psychiatry 27(6):451–454. https://doi.org/10.1016/j.eurpsy.2011.01.003
Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE et al (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302(19):2119–2126. https://doi.org/10.1001/jama.2009.1622
Evcimen H, Mania I, Mathews M, Basil B (2007) Psychosis precipitated by acetyl-l-carnitine in a patient with bipolar disorder. Prim Care Companion J Clin Psychiatry 9(1):71–72
Fasinu PS, Bouic PJ, Rosenkranz B (2012) An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol 3:69. https://doi.org/10.3389/fphar.2012.00069
Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M (2016) N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry 77(4):e457–e466. https://doi.org/10.4088/JCP.15r09984
Frankenburg FR (2009) Folate supplementation: is it safe and effective? J Clin Psychiatry 70(5):767 Author reply 767–769
Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113(1):31–35. https://doi.org/10.1111/j.1600-0447.2005.00660.x
Fürst R, Zündorf I (2015) Evidence-based phytotherapy in Europe: where do we stand? Planta Med 81(12–13):962–967. https://doi.org/10.1055/s-0035-1545948
Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN et al (2016) S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev 10:CD011286. https://doi.org/10.1002/14651858.CD011286.pub2
Gijsman HJ, van Gerven JMA, de Kam ML, Schoemaker RC, Pieters MSM, Weemaes M et al (2002) Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol 22(2):183–189
Gnerre C, von Poser GL, Ferraz A, Viana A, Testa B, Rates SM (2001) Monoamine oxidase inhibitory activity of some Hypericum species native to South Brazil. J Pharm Pharmacol 53(9):1273–1279
Goodison G, Overeem K, de Monte V, Siskind D (2017) Mania associated with self-prescribed acetyl-l-carnitine in a man with bipolar I disorder. Aust Psychiatry 25(1):13–14. https://doi.org/10.1177/1039856216658831
Green AR, Aronson JK, Curzon G, Woods HF (1980) Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol 10(6):603–610
Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC (2015) The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76(2):155–162. https://doi.org/10.4088/JCP.14m09298
Gregoretti B, Stebel M, Candussio L, Crivellato E, Bartoli F, Decorti G (2004) Toxicity of Hypericum perforatum (St. John’s wort) administered during pregnancy and lactation in rats. Toxicol Appl Pharmacol 200(3):201–205. https://doi.org/10.1016/j.taap.2004.04.020
Gross BW, Gillio M, Rinehart CD, Lynch CA, Rogers FB (2017) Omega-3 fatty acid supplementation and warfarin: a lethal combination in traumatic brain injury. J Trauma Nurs 24(1):15–18. https://doi.org/10.1097/JTN.0000000000000256
Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F (2014a) Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative Med Cell Longev 2014:313570. https://doi.org/10.1155/2014/313570
Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C et al (2014b) Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 9(5):e96905. https://doi.org/10.1371/journal.pone.0096905
Hara J, Shankle WR, Barrentine LW, Curole MV (2016) Novel therapy of hyperhomocysteinemia in mild cognitive impairment, Alzheimer’s disease, and other dementing disorders. J Nutr Health Aging 20(8):825–834. https://doi.org/10.1007/s12603-016-0688-z
Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F et al (2003) S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ) 64:1–3
Hirsch S, Sanchez H, Albala C, de la Maza MP, Barrera G, Leiva L, Bunout D (2009) Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol 21(4):436–439. https://doi.org/10.1097/MEG.0b013e328306ccdb
Hu M, Fan L, Zhou H-H, Tomlinson B (2012) Theranostics meets traditional Chinese medicine: rational prediction of drug-herb interactions. Expert Rev Mol Diagn 12(8):815–830. https://doi.org/10.1586/erm.12.126
Hung SK, Perry R, Ernst E (2011) The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine 18(4):235–244. https://doi.org/10.1016/j.phymed.2010.08.014
Iovieno N, Dalton ED, Fava M, Mischoulon D (2011) Second-tier natural antidepressants: review and critique. J Affect Disord 130(3):343–357. https://doi.org/10.1016/j.jad.2010.06.010
Keck PE, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA et al (2006) Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60(9):1020–1022. https://doi.org/10.1016/j.biopsych.2006.03.056
Kelly GS (2001) Rhodiola rosea: a possible plant adaptogen. Altern Med Rev 6(3):293–302
Kennedy SH (2013) A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord 15(2). https://doi.org/10.4088/PCC.12r01420
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105
Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, Eisenberg DM (2001) The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 158(2):289–294. https://doi.org/10.1176/appi.ajp.158.2.289
Kleinman AM (1975) The symbolic context of Chinese medicine: a comparative approach to the study of traditional medical and psychiatric forms of care in Chinese culture. Am J Chin Med 3(2):103–124
Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17(3):208–221
Lewicki S, Skopińska-Różewska E, Lewicka A, Zdanowski R (2017) Long-term supplementation of Rhodiola kirilowii extracts during pregnancy and lactation does not affect mother health status. J Matern Fetal Neonatal Med:1–7. https://doi.org/10.1080/14767058.2017.1393069
Lewis MD, Hibbeln JR, Johnson JE, Lin YH, Hyun DY, Loewke JD (2011) Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. J Clin Psychiatry 72(12):1585–1590. https://doi.org/10.4088/JCP.11m06879
Lin P-Y, Su K-P (2007) A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68(7):1056–1061
Linde K, Berner MM, Kriston L (2008) St John’s wort for major depression. Cochrane Database Syst Rev 4:CD000448. https://doi.org/10.1002/14651858.CD000448.pub3
Lishmanov IB, Trifonova ZV, Tsibin AN, Maslova LV, Dement’eva LA (1987) Plasma beta-endorphin and stress hormones in stress and adaptation. Biull Eksp Biol Med 103(4):422–424
Lishmanov IB, Naumova AV, Afanas’ev SA, Maslov LN (1997) Contribution of the opioid system to realization of inotropic effects of Rhodiola rosea extracts in ischemic and reperfusion heart damage in vitro. Eksp Klin Farmakol 60(3):34–36
Maes M, Jacobs MP, Suy E, Vandewoude M, Minner B, Raus J (1990) Effects of dexamethasone on the availability of L-tryptophan and on the insulin and FFA concentrations in unipolar depressed patients. Biol Psychiatry 27(8):854–862
Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K et al (2013) A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry 47(6):564–568. https://doi.org/10.1177/0004867413481631
Maniscalco I, Toffol E, Giupponi G, Conca A (2015) The interaction of Rhodiola rosea and antidepressants. A case report. Neuropsychiatrie 29(1):36–38. https://doi.org/10.1007/s40211-014-0124-8
Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HFS, Puryear LJ (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160(5):996–998. https://doi.org/10.1176/appi.ajp.160.5.996
Marangell LB, Martinez JM, Zboyan HA, Chong H, Puryear LJ (2004) Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress Anxiety 19(1):20–23. https://doi.org/10.1002/da.10148
Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J-S, Chavin KD (2003) Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290(11):1500–1504. https://doi.org/10.1001/jama.290.11.1500
Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D et al (2011) Acetyl-l-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuro-Psychopharmacol Biol Psychiatry 35(4):953–958. https://doi.org/10.1016/j.pnpbp.2011.01.013
Maslova LV, Kondrat’ev BI, Maslov LN, Lishmanov IB (1994) The cardioprotective and antiadrenergic activity of an extract of Rhodiola rosea in stress. Eksp Klin Farmakol 57(6):61–63
Meltzer H, Bastani B, Jayathilake K, Maes M (1997) Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 17(1):1–11. https://doi.org/10.1016/S0893-133X(96)00280-1
Ming DS, Hillhouse BJ, Guns ES, Eberding A, Xie S, Vimalanathan S, Towers GHN (2005) Bioactive compounds from Rhodiola rosea (Crassulaceae). Phytother Res 19(9):740–743. https://doi.org/10.1002/ptr.1597
Mischoulon D (2004) Nutraceuticals in psychiatry, Part 1: Social, technical, economic, and political perspectives. Contemp Psychiatry 2(11):1–6
Mischoulon D (2009) Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin N Am 36(4):789–807, x. https://doi.org/10.1016/j.ogc.2009.10.005
Mischoulon D, Fava M (2002) Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 76(5):1158S–1161S
Mischoulon D, Raab MF (2007) The role of folate in depression and dementia. J Clin Psychiatry 68(Suppl 10):28–33
Mischoulon D, Rosenbaum JF (1999) The use of natural remedies in psychiatry: a commentary. Harv Rev Psychiatry 6(5):279–283
Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL et al (2008) A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol 18(9):639–645. https://doi.org/10.1016/j.euroneuro.2008.04.011
Mischoulon D, Fava M, Stahl SM (2009) Folate supplementation: is it safe and effective? [response to letter]. J Clin Psychiatry 70(5):767–769
Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI (2012a) Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry 73(6):843–848. https://doi.org/10.4088/JCP.11m07139
Mischoulon D, Brill CD, Ameral VE, Fava M, Yeung AS (2012b) A pilot study of acupuncture monotherapy in patients with major depressive disorder. J Affect Disord 141(2–3):469–473. https://doi.org/10.1016/j.jad.2012.03.023
Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV et al (2012c) Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr 17(2):76–86
Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L et al (2014) A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry 75(4):370–376. https://doi.org/10.4088/JCP.13m08591
Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M (2015) A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry 76(1):54–61. https://doi.org/10.4088/JCP.14m08986
Mocking RJT, Harmsen I, Assies J, Koeter MWJ, Ruhé HG, Schene AH (2016) Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 6:e756. https://doi.org/10.1038/tp.2016.29
Mohamed M-EF, Frye RF (2011) Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med 77(4):311–321. https://doi.org/10.1055/s-0030-1250457
Moore CM, Breeze JL, Kukes TJ, Rose SL, Dager SR, Cohen BM, Renshaw PF (1999) Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 45(9):1197–1202
Mukai T, Kishi T, Matsuda Y, Iwata N (2014) A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 29(1):55–63. https://doi.org/10.1002/hup.2369
Na DH, Ji HY, Park EJ, Kim MS, Liu K-H, Lee HS (2011) Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res 34(11):1829–1842. https://doi.org/10.1007/s12272-011-1105-0
National Institutes of Health (2010) Fact Sheet: complementary and alternative medicine, October. https://report.nih.gov/NIHfactsheets/Pdfs/ComplementaryandAlternativeMedicine(NCCAM).pdf
Necyk C, Khamba B, Chue P, Urichuk L, Snaterse M, Vohra S (2016) Study of natural health product-drug adverse reactions (S.O.N.A.R.) in patients seeking mental health services. Curr Med Res Opin 32(8):1335–1343. https://doi.org/10.1185/03007995.2016.1174109
Nierenberg AA, Lund HG, Mischoulon D (2008) St. John’s wort: a critical evaluation of the evidence of antidepressant effects. In: Mischoulon D, Rosenbaum J (eds) Natural medications for psychiatric disorders: considering the alternatives, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 27–38
Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV (2013) Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry 47(1):26–42. https://doi.org/10.1177/0004867412449303
Okereke OI, Reynolds CF 3rd, Mischoulon D, Chang G, Cook NR, Copeland T et al (2018) The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemp Clin Trials 68:133–145
Ostadrahimi A, Salehi-Pourmehr H, Mohammad-Alizadeh-Charandabi S, Heidarabady S, Farshbaf-Khalili A (2017) The effect of perinatal fish oil supplementation on neurodevelopment and growth of infants: a randomized controlled trial. Eur J Nutr. https://doi.org/10.1007/s00394-017-1512-1
Ostermann T, Lauche R, Cramer H, Dobos G (2017) Comparative cost analysis of inpatient integrative medicine – results of a pilot study. Complement Ther Med 32:129–133. https://doi.org/10.1016/j.ctim.2016.11.009
Pal D, Mitra AK (2006) MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78(18):2131–2145. https://doi.org/10.1016/j.lfs.2005.12.010
Panossian A, Hamm R, Wikman G, Efferth T (2014) Mechanism of action of Rhodiola, salidroside, tyrosol and triandrin in isolated neuroglial cells: an interactive pathway analysis of the downstream effects using RNA microarray data. Phytomedicine 21(11):1325–1348. https://doi.org/10.1016/j.phymed.2014.07.008
Papakostas GI (2009) Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry 70(Suppl 5):18–22. https://doi.org/10.4088/JCP.8157su1c.04
Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M (2010) S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167(8):942–948. https://doi.org/10.1176/appi.ajp.2009.09081198
Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A et al (2012) L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 169(12):1267–1274. https://doi.org/10.1176/appi.ajp.2012.11071114
Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (2016) Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 21(1):71–79. https://doi.org/10.1038/mp.2015.22
Risser AL, Mazur LJ (1995) Use of folk remedies in a Hispanic population. Arch Pediatr Adolesc Med 149(9):978–981
Rodríguez-Landa JF, Contreras CM (2003) A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10(8):688–699. https://doi.org/10.1078/0944-7113-00340
Safer DJ (2017) Differing antidepressant maintenance methodologies. Contemp Clin Trials 61:87–95. https://doi.org/10.1016/j.cct.2017.07.021
Salazar MR (2000) Alpha lipoic acid: a novel treatment for depression. Med Hypotheses 55(6):510–512. https://doi.org/10.1054/mehy.2000.1103
Sarris J, Kavanagh DJ (2009) Kava and St. John’s wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med (New York, NY) 15(8):827–836. https://doi.org/10.1089/acm.2009.0066
Sarris J, Mischoulon D, Schweitzer I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73(1):81–86. https://doi.org/10.4088/JCP.10r06710
Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI et al (2015) Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized clinical trial. Pharmacopsychiatry 48(4–5):141–144. https://doi.org/10.1055/s-0035-1549928
Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H et al (2007) Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81(5):669–678. https://doi.org/10.1038/sj.clpt.6100191
Seifritz E, Hatzinger M, Holsboer-Trachsler E (2016) Efficacy of Hypericum extract WS® 5570 compared with paroxetine in patients with a moderate major depressive episode – a subgroup analysis. Int J Psychiatry Clin Pract 20(3):126–132. https://doi.org/10.1080/13651501.2016.1179765
Shankle WR, Hara J, Barrentine LW, Curole MV (2016) CerefolinNAC therapy of hyperhomocysteinemia delays cortical and white matter atrophy in Alzheimer’s disease and cerebrovascular disease. J Alzheimers Dis 54(3):1073–1084. https://doi.org/10.3233/JAD-160241
Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H et al (2017) S-adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research. J Clin Psychiatry 78(6):e656–e667. https://doi.org/10.4088/JCP.16r11113
Shaw K, Turner J, Del Mar C (2002) Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 1:CD003198. https://doi.org/10.1002/14651858.CD003198
Silva MCC, de Sousa CNS, Sampaio LRL, Ximenes NC, Araújo PVP, da Silva JC et al (2013) Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression? Naunyn Schmiedeberg’s Arch Pharmacol 386(8):685–695. https://doi.org/10.1007/s00210-013-0867-y
Silva MCC, de Sousa CNS, Gomes PXL, de Oliveira GV, Araújo FYR, Ximenes NC et al (2016) Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 64:142–148. https://doi.org/10.1016/j.pnpbp.2015.08.002
Spence J, Chintapenta M, Kwon HI, Blaszczyk AT (2017) A brief review of three common supplements used in Alzheimer’s disease. Consult Pharm 32(7):412–414. https://doi.org/10.4140/TCP.n.2017.412
Stoll AL (2008) Omega-3 fatty acids in mood disorders: a review of neurobiologic and clinical actions. In: Mischoulon D, Rosenbaum J (eds) Natural medications for psychiatric disorders: considering the alternatives, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 39–67
Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56(5):407–412
Stolzenberg-Solomon RZ, Chang S-C, Leitzmann MF, Johnson KA, Johnson C, Buys SS et al (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr 83(4):895–904. https://doi.org/10.1093/ajcn/83.4.895
Sublette ME, Ellis SP, Geant AL, Mann JJ (2011) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 72(12):1577–1584. https://doi.org/10.4088/JCP.10m06634
Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L (1987) L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 13(7):417–423
Trebatická J, Hradečná Z, Böhmer F, Vaváková M, Waczulíková I, Garaiova I et al (2017) Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents: a pilot study. Child Adolesc Psychiatry Ment Health 11:30. https://doi.org/10.1186/s13034-017-0167-2
Turkanovic J, Ward MB, Gerber JP, Milne RW (2017) Effect of garlic, gingko, and St. John’s wort extracts on the pharmacokinetics of fexofenadine: a mechanistic study. Drug Metab Dispos 45(5):569–575. https://doi.org/10.1124/dmd.116.073528
Turner P, Kantaria R, Young AH (2014) A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol (Oxford, England) 28(2):85–98. https://doi.org/10.1177/0269881113507640
U.S. Food and Drug Administration (n.d.) Advice about eating fish: what pregnant women and parents should know. Washington. https://www.fda.gov/downloads/Food/ResourcesForYou/Consumers/UCM536321.pdf
van Diermen D, Marston A, Bravo J, Reist M, Carrupt P-A, Hostettmann K (2009) Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 122(2):397–401. https://doi.org/10.1016/j.jep.2009.01.007
Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S (2017) Acetyl-l-carnitine supplementation and the treatment for depressive symptoms: a systematic review and meta-analysis. Psychosom Med. https://doi.org/10.1097/PSY.0000000000000537
Volchegorskiĭ IA, Rassokhina LM, Koliadich MI, Alekseev MI (2011) Comparative study of alpha-lipoic acid and mexidol effects on affective status, cognitive functions and quality of life in diabetes mellitus patients. Eksp Klin Farmakol 74(11):17–23
Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E et al (2013) Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (London, England) 381(9871):1029–1036. https://doi.org/10.1016/S0140-6736(12)62001-7
Wallace P (2003) Baseball player’s death renews ephedra debate. Food Chemical News, 24 Feb, 22
Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U (2014) A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res 53:30–37. https://doi.org/10.1016/j.jpsychires.2014.02.005
Yeung A, Mischoulon D, Alpert J, Ma Y, Fava M (2007) Acupuncture for major depressive disorder: has its efficacy been disproved? J Clin Psychiatry 68(10):1617 Author reply 1617–1618
Zanardi R, Smeraldi E (2006) A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 16(4):281–287. https://doi.org/10.1016/j.euroneuro.2005.10.005
Zhang Y, Lu L, Victor DW, Xin Y, Xuan S (2016) Ursodeoxycholic acid and S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: a meta-analysis. Hepat Mon 16(8):e38558. https://doi.org/10.5812/hepatmon.38558
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Mischoulon, D., Rapaport, M.H. (2018). Current Role of Herbal and Natural Preparations. In: Macaluso, M., Preskorn, S. (eds) Antidepressants. Handbook of Experimental Pharmacology, vol 250. Springer, Cham. https://doi.org/10.1007/164_2018_152
Download citation
DOI: https://doi.org/10.1007/164_2018_152
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10948-6
Online ISBN: 978-3-030-10949-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)